BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Former United Launch Alliance CEO Tory Bruno joins competitor Blue Origin for national security projects - 2Chinese fossils reveal a primordial burst of animal evolution
- 3In these U.S. groups, deaths now exceed births. What’s happening?
- 4The Force of Organic product: 10 Assortments That Improve Your Wellbeing
- 5Scientists sent a menstrual cup to space. This is how it went
- JW Marriott Tokyo: an elegant retreat amid whirlwind of the city
- Will your baby get a hep B vaccine? What RFK panel's ruling means.
- Surveys of Music Collections by Film Stars
- Single women risk rape and exploitation in search for better life in Europe
- A Manual for Nations to Head out To
- Figure out How to Recognize Early Indications of Depressions
- NASA's Artemis 2 astronauts are cruising to the moon. So why are they doing CPR tests today?
- Investigate Business Mastercard Choices for Better Rewards and Rewards
- NAFFIC and Aware to Launch First China-Europe Digital Product Passport
